{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:29:49Z","timestamp":1769185789896,"version":"3.49.0"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.intimp.2022.109161","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T03:05:09Z","timestamp":1660791909000},"page":"109161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine"],"prefix":"10.1016","volume":"111","author":[{"given":"Moein","family":"Shirzad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Nourigorji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atefe","family":"Sajedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faeze","family":"Rasti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Sourani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed","family":"Mostafa Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Yousef","family":"Memar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109161_b0005","doi-asserted-by":"crossref","first-page":"200463","DOI":"10.1148\/radiol.2020200463","article-title":"Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection","author":"Bernheim","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.intimp.2022.109161_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.02.016","article-title":"Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China","author":"Yang","year":"2020","journal-title":"J. Infect."},{"issue":"5","key":"10.1016\/j.intimp.2022.109161_b0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/RLI.0000000000000670","article-title":"Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features","volume":"55","author":"Wu","year":"2020","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.intimp.2022.109161_b0020","doi-asserted-by":"crossref","unstructured":"K. Dhama, K. Sharun, R. Tiwari, S. Sircar, S. Bhat, Y.S. Malik, K.P. Singh, W. Chaicumpa, D.K. Bonilla-Aldana, A.J. Rodriguez-Morales, Coronavirus disease 2019\u2013COVID-19, 2020.","DOI":"10.20944\/preprints202003.0001.v1"},{"issue":"9366","key":"10.1016\/j.intimp.2022.109161_b0025","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(03)13077-2","article-title":"Coronavirus as a possible cause of severe acute respiratory syndrome","volume":"361","author":"Peiris","year":"2003","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2022.109161_b0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/resp.13196","article-title":"MERS, SARS and other coronaviruses as causes of pneumonia","volume":"23","author":"Yin","year":"2018","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0035","first-page":"141","article-title":"Coronavirus (COVID-19): Let\u2019s Prevent Not Panic","volume":"32","author":"Mukhtar","year":"2020","journal-title":"Journal of Ayub Medical College Abbottabad"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0040","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.intimp.2022.109161_b0045","unstructured":"X.-W. Xu, X.-X. Wu, X.-G. Jiang, K.-J. Xu, L.-J. Ying, C.-L. Ma, S.-B. Li, H.-Y. Wang, S. Zhang, H.-N. Gao, Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series, bmj 368 (2020)."},{"key":"10.1016\/j.intimp.2022.109161_b0050","doi-asserted-by":"crossref","unstructured":"A.R. Fehr, S. Perlman, Coronaviruses: an overview of their replication and pathogenesis, Coronaviruses, Springer, 2015, pp. 1\u201323.","DOI":"10.1007\/978-1-4939-2438-7_1"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.intimp.2022.109161_b0060","doi-asserted-by":"crossref","unstructured":"D. Brian, R. Baric, Coronavirus genome structure and replication, Coronavirus replication and reverse genetics, Springer, 2005, pp. 1-30.","DOI":"10.1007\/3-540-26765-4_1"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0065","first-page":"1","article-title":"2019 novel coronavirus (COVID-19) outbreak: a review of the current literature","volume":"4","author":"Sahin","year":"2020","journal-title":"EJMO"},{"issue":"7592","key":"10.1016\/j.intimp.2022.109161_b0070","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature17200","article-title":"Pre-fusion structure of a human coronavirus spike protein","volume":"531","author":"Kirchdoerfer","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2022.109161_b0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.intimp.2022.109161_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2020.06.014","article-title":"A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization","author":"Johnson","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"12","key":"10.1016\/j.intimp.2022.109161_b0085","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.18632\/aging.103383","article-title":"Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis","volume":"12","author":"Xu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.intimp.2022.109161_b0090","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/S1525-0016(16)34174-0","article-title":"565. CCR5-Uco-TALEN\u2013A Novel Transcription Activator-Like Effector Nuclease That Mediates High-Efficiency Knockout of HIV Co-Receptor CCR5 in Primary T Cells After mRNA Transfection","volume":"23","author":"Mock","year":"2015","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2022.109161_b0095","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/art.39982","article-title":"CRISPR\/Cas9 editing of murine induced pluripotent stem cells for engineering inflammation-resistant tissues","volume":"69","author":"Brunger","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109161_b0100","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/j.drudis.2021.06.005","article-title":"Recent progress on rapid SARS-CoV-2\/COVID-19 detection by CRISPR-Cas13-based platforms","volume":"26","author":"Aquino-Jarquin","year":"2021","journal-title":"Drug Discovery Today"},{"issue":"4","key":"10.1016\/j.intimp.2022.109161_b0105","doi-asserted-by":"crossref","first-page":"100245","DOI":"10.1016\/j.xcrm.2021.100245","article-title":"A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses","volume":"2","author":"Lin","year":"2021","journal-title":"Cell Reports Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-021-02001-8","article-title":"Amplification-free RNA detection with CRISPR\u2013Cas13","volume":"4","author":"Shinoda","year":"2021","journal-title":"Commun. Biol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109161_b0115","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1021\/acsptsci.0c00071","article-title":"Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19","volume":"3","author":"Nalawansha","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2022.109161_b0120","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2174\/18734316MTEwtNTgrw","article-title":"Targeted delivery of CRISPR\/Cas13 as a promising therapeutic approach to treat SARS-CoV-2","volume":"22","author":"Abbaszadeh-Goudarzi","year":"2021","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109161_b0125","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1021\/acssynbio.1c00181","article-title":"A Novel Miniature CRISPR-Cas13 System for SARS-CoV-2 Diagnostics","volume":"10","author":"Mahas","year":"2021","journal-title":"ACS Synth. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109161_b0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nbt.3525","article-title":"Quality cell therapy manufacturing by design","volume":"34","author":"Lipsitz","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2022.109161_b0135","doi-asserted-by":"crossref","unstructured":"N. Sher, R. Ofir, Clinical Development and Commercialization of Placenta-Derived Cell Therapy, Perinatal Stem Cells, Elsevier, 2018, pp. 357-375.","DOI":"10.1016\/B978-0-12-812015-6.00026-1"},{"key":"10.1016\/j.intimp.2022.109161_b0140","doi-asserted-by":"crossref","unstructured":"S.I. Savitz, K. Parsha, Enhancing Stroke Recovery with Cellular Therapies, Stroke, Elsevier, 2016, pp. 981-991.","DOI":"10.1016\/B978-0-323-29544-4.00060-8"},{"issue":"2","key":"10.1016\/j.intimp.2022.109161_b0145","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/JCN.0b013e318197a6a5","article-title":"Introduction to stem cell therapy","volume":"24","author":"Biehl","year":"2009","journal-title":"J. Cardiovasc. Nursing"},{"key":"10.1016\/j.intimp.2022.109161_b0150","doi-asserted-by":"crossref","first-page":"119627","DOI":"10.1016\/j.biomaterials.2019.119627","article-title":"Biomaterial-assisted scalable cell production for cell therapy","volume":"230","author":"Chen","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.intimp.2022.109161_b0155","unstructured":"R. Champlin, Selection of autologous or allogeneic transplantation, Cancer Medicine. 6th. BC Decker, 2003."},{"issue":"4","key":"10.1016\/j.intimp.2022.109161_b0160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1947603514534681","article-title":"Cartilage repair with autologous bone marrow mesenchymal stem cell transplantation: review of preclinical and clinical studies","volume":"5","author":"Yamasaki","year":"2014","journal-title":"Cartilage"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-019-1165-5","article-title":"Stem cells: past, present, and future","volume":"10","author":"Zakrzewski","year":"2019","journal-title":"Stem Cell Res. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2022.109161_b0170","first-page":"06","article-title":"A Review on the Discovery of Different Stem Cells and the Potential Therapies based on these Cells","volume":"2","author":"Nautiyal","year":"2019","journal-title":"Int. J. Health Biol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2022.109161_b0175","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jgeb.2018.09.002","article-title":"Recent advances in stem cells therapy: A focus on cancer, Parkinson\u2019s and Alzheimer\u2019s","volume":"16","author":"Fleifel","year":"2018","journal-title":"J. Genet. Eng. Biotechnol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109161_b0180","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/j.jaci.2009.09.032","article-title":"Embryonic and adult stem cell therapy","volume":"125","author":"Brignier","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109161_b0185","doi-asserted-by":"crossref","first-page":"462","DOI":"10.14336\/AD.2020.0301","article-title":"Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia","volume":"11","author":"Shetty","year":"2020","journal-title":"Aging Dis."},{"key":"10.1016\/j.intimp.2022.109161_b0190","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9628536","article-title":"Challenges and controversies in human mesenchymal stem cell therapy","volume":"2019","author":"Lukomska","year":"2019","journal-title":"Stem Cells Int."},{"issue":"21","key":"10.1016\/j.intimp.2022.109161_b0195","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19","volume":"383","author":"Group","year":"2020","journal-title":"N Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-01849-7","article-title":"The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm","volume":"11","author":"Kavianpour","year":"2020","journal-title":"Stem Cell Res. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2022.109161_b0205","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respiratory Med."},{"issue":"10223","key":"10.1016\/j.intimp.2022.109161_b0210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2022.109161_b0215","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s11684-020-0810-9","article-title":"Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19","volume":"14","author":"Tang","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2022.109161_b0220","doi-asserted-by":"crossref","DOI":"10.1089\/scd.2020.0071","article-title":"Stem Cell-Based Therapy for Coronavirus Disease 2019","author":"Zhao","year":"2020","journal-title":"Stem Cells Dev."},{"issue":"31","key":"10.1016\/j.intimp.2022.109161_b0225","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021429","article-title":"Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report","volume":"99","author":"Liang","year":"2020","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0230","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","author":"Li","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00286-5","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial","volume":"5","author":"Meng","year":"2020","journal-title":"Signal Transduction Targeted Therapy"},{"key":"10.1016\/j.intimp.2022.109161_b0240","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3389\/fmed.2020.594495","article-title":"Body localization of ACE-2: On the trail of the keyhole of SARS-CoV-2","volume":"7","author":"Salamanna","year":"2020","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.109161_b0245","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/sctm.20-0385","article-title":"Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection","volume":"10","author":"Avanzini","year":"2021","journal-title":"Stem Cells Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109161_b0250","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis."},{"key":"10.1016\/j.intimp.2022.109161_b0255","doi-asserted-by":"crossref","first-page":"102066","DOI":"10.1016\/j.scr.2020.102066","article-title":"A safety consideration of mesenchymal stem cell therapy on COVID-19","volume":"49","author":"Cao","year":"2020","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.intimp.2022.109161_b0260","first-page":"1","article-title":"Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy","author":"Hong","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.intimp.2022.109161_b0265","first-page":"1","article-title":"Cell-based therapy for severe COVID-19 patients: clinical trials and cost-utility","author":"Golchin","year":"2020","journal-title":"Stem Cell Rev. Reports"},{"key":"10.1016\/j.intimp.2022.109161_b0270","doi-asserted-by":"crossref","first-page":"118588","DOI":"10.1016\/j.lfs.2020.118588","article-title":"Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics","author":"Yadav","year":"2020","journal-title":"Life Sci."},{"issue":"17","key":"10.1016\/j.intimp.2022.109161_b0275","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.3390\/ijms21176351","article-title":"Natural killer cell dysfunction and its role in COVID-19","volume":"21","author":"van Eeden","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2022.109161_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01512","article-title":"Flattening the COVID-19 curve with natural killer cell based immunotherapies","volume":"11","author":"Market","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109161_b0285","doi-asserted-by":"crossref","first-page":"106455","DOI":"10.1016\/j.intimp.2020.106455","article-title":"The possible of immunotherapy for COVID-19: A systematic review","author":"AminJafari","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.109161_b0290","article-title":"Obesity, COVID-19 and immunotherapy: the complex relationship!","author":"Finelli","year":"2020","journal-title":"Future Med."},{"key":"10.1016\/j.intimp.2022.109161_b0295","article-title":"Immunobiology and immunotherapy of COVID-19: A clinically updated overview","author":"Esmaeilzadeh","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"10223","key":"10.1016\/j.intimp.2022.109161_b0300","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"The Lancet"},{"issue":"10223","key":"10.1016\/j.intimp.2022.109161_b0305","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The lancet"},{"issue":"2","key":"10.1016\/j.intimp.2022.109161_b0310","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.micinf.2012.10.008","article-title":"Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response","volume":"15","author":"Li","year":"2013","journal-title":"Microbes Infect."},{"key":"10.1016\/j.intimp.2022.109161_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109161_b0320","doi-asserted-by":"crossref","unstructured":"P. Mosaddeghi, M. Negahdaripour, Z. Dehghani, M. Farahmandnejad, M. Moghadami, N. Nezafat, S.M. Masoompour, Therapeutic approaches for COVID-19 based on the dynamics of interferon-mediated immune responses, 2020.","DOI":"10.2174\/1574362416666210120104636"},{"issue":"10238","key":"10.1016\/j.intimp.2022.109161_b0325","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2022.109161_b0330","first-page":"231","article-title":"The rise and fall in therapeutic candidates for COVID-19","volume":"45","author":"Negahdaripour","year":"2020","journal-title":"Iranian J. Med. Sci."},{"key":"10.1016\/j.intimp.2022.109161_b0335","doi-asserted-by":"crossref","unstructured":"E. Sallard, F.-X. Lescure, Y. Yazdanpanah, F. Mentre, N. Peiffer-Smadja, A. Florence, Y. Yazdanpanah, F. Mentre, F.-X. Lescure, N. Peiffer-Smadja, Type 1 interferons as a potential treatment against COVID-19, Antiviral Res. (2020) 104791.","DOI":"10.1016\/j.antiviral.2020.104791"},{"key":"10.1016\/j.intimp.2022.109161_b0340","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3389\/fimmu.2017.00621","article-title":"Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients","volume":"8","author":"Phillips","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109161_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109161_b0350","doi-asserted-by":"crossref","first-page":"106688","DOI":"10.1016\/j.intimp.2020.106688","article-title":"Subcutaneous administration of Interferon beta-1a for COVID-19: A non-controlled prospective trial","author":"Dastan","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-03048-5","article-title":"Interferon beta-1a for COVID-19: critical importance of the administration route","volume":"24","author":"Jalkanen","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.intimp.2022.109161_b0360","first-page":"1","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"21","key":"10.1016\/j.intimp.2022.109161_b0365","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial","volume":"324","author":"Self","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0370","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.intimp.2022.109161_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.intimp.2022.109161_b0380","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.7150\/ijbs.45123","article-title":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2","volume":"16","author":"Zhou","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"20","key":"10.1016\/j.intimp.2022.109161_b0385","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2022.109161_b0390","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.3389\/fimmu.2020.01648","article-title":"Cytokine storm in COVID-19\u2014immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper","volume":"11","author":"Bhaskar","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109161_b0395","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","author":"Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2022.109161_b0400","doi-asserted-by":"crossref","unstructured":"R. Davies, E. Choy, Clinical experience of IL-6 blockade in rheumatic diseases\u2014implications on IL-6 biology and disease pathogenesis, Seminars in immunology, Elsevier, 2014, pp. 97-104.","DOI":"10.1016\/j.smim.2013.12.002"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0405","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.intimp.2022.109161_b0410","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0415","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","article-title":"Tocilizumab\u2013A novel therapy for non-organ-specific autoimmune diseases","volume":"26","author":"Kaly","year":"2012","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109161_b0420","first-page":"102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease (COVID-19)-induced cytokine release syndrome (CRS)?","volume":"2020","author":"Liu","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2022.109161_b0425","doi-asserted-by":"crossref","unstructured":"N. Wadud, N. Ahmed, M.M. Shergil, M. Khan, M.G. Krishna, A. Gilani, S. El Zarif, J. Galaydick, K. Linga, S. Koor, Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration, medRxiv (2020).","DOI":"10.1101\/2020.05.13.20100081"},{"key":"10.1016\/j.intimp.2022.109161_b0430","doi-asserted-by":"crossref","unstructured":"E.J. Giamarellos-Bourboulis, M.G. Netea, N. Rovina, K. Akinosoglou, A. Antoniadou, N. Antonakos, G. Damoraki, T. Gkavogianni, M.-E. Adami, P. Katsaounou, Complex immune dysregulation in COVID-19 patients with severe respiratory failure, Cell Host & Microbe 2020.","DOI":"10.1016\/j.chom.2020.04.009"},{"issue":"7","key":"10.1016\/j.intimp.2022.109161_b0435","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: A single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2022.109161_b0440","article-title":"Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis","author":"Guo","year":"2020","journal-title":"BioRxiv"},{"issue":"5","key":"10.1016\/j.intimp.2022.109161_b0445","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diii.2020.03.010","article-title":"Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab","volume":"101","author":"Cellina","year":"2020","journal-title":"Diagn. Interventional Imaging"},{"key":"10.1016\/j.intimp.2022.109161_b0450","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25897","article-title":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection","author":"Di Giambenedetto","year":"2020","journal-title":"J. Med. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109161_b0455","first-page":"529","article-title":"Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19","volume":"38","author":"Sciascia","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109161_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmal.2020.05.001","article-title":"Tocilizumab therapy reduced intensive care unit admissions and\/or mortality in COVID-19 patients","author":"Klopfenstein","year":"2020","journal-title":"M\u00e9decine et Maladies Infectieuses"},{"key":"10.1016\/j.intimp.2022.109161_b0465","doi-asserted-by":"crossref","unstructured":"M. Roumier, R. Paule, G. Matthieu, A. Vall\u00e9e, F. ACKERMANN, Interleukin-6 blockade for severe COVID-19, medrxiv (2020).","DOI":"10.1101\/2020.04.20.20061861"},{"key":"10.1016\/j.intimp.2022.109161_b0470","article-title":"Tocilizumab for the Treatment of Severe COVID-19","author":"Alattar","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2022.109161_b0475","doi-asserted-by":"crossref","unstructured":"P. Mehta, D.F. McAuley, M. Brown, E. Sanchez, R.S. Tattersall, J.J. Manson, H.A.S. Collaboration, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet (London, England) 395(10229) (2020) 1033.","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"10.1016\/j.intimp.2022.109161_b0480","first-page":"1","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.109161_b0485","doi-asserted-by":"crossref","first-page":"106924","DOI":"10.1016\/j.intimp.2020.106924","article-title":"Immunotherapeutic approaches to curtail COVID-19","author":"Owji","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109161_b0490","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2217\/fvl-2020-0137","article-title":"Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future","volume":"15","author":"Rehman","year":"2020","journal-title":"Future Virol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109161_b0495","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4110\/in.2015.15.2.51","article-title":"Recent advances of vaccine adjuvants for infectious diseases","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw"},{"key":"10.1016\/j.intimp.2022.109161_b0500","article-title":"Viral targets for vaccines against COVID-19","author":"Dai","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.109161_b0505","doi-asserted-by":"crossref","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 Vaccine: A comprehensive status report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res."},{"issue":"4","key":"10.1016\/j.intimp.2022.109161_b0510","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/vaccines8040739","article-title":"Efforts at COVID-19 Vaccine Development: Challenges and Successes","volume":"8","author":"Haque","year":"2020","journal-title":"Vaccines"},{"issue":"415","key":"10.1016\/j.intimp.2022.109161_b0515","article-title":"Virus Irradiation and COVID-19 Disease","volume":"8","author":"Durante","year":"2020","journal-title":"Front. Phys."},{"issue":"6","key":"10.1016\/j.intimp.2022.109161_b0520","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12249-020-01744-7","article-title":"The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation","volume":"21","author":"Wang","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.intimp.2022.109161_b0525","doi-asserted-by":"crossref","first-page":"173751","DOI":"10.1016\/j.ejphar.2020.173751","article-title":"COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies","volume":"892","author":"Rawat","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109161_b0530","article-title":"SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies","author":"Huang","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"issue":"6499","key":"10.1016\/j.intimp.2022.109161_b0535","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science (New York, N.Y.)"},{"issue":"12","key":"10.1016\/j.intimp.2022.109161_b0540","first-page":"527","article-title":"Immunotherapeutics for Covid-19 and post vaccination surveillance, 3","volume":"10","author":"Sampath Kumar","year":"2020","journal-title":"Biotech"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0545","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduction Targeted Therapy"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0550","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus vaccine development: from SARS and MERS to COVID-19","volume":"27","author":"Li","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"7830","key":"10.1016\/j.intimp.2022.109161_b0555","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.intimp.2022.109161_b0560","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"issue":"7830","key":"10.1016\/j.intimp.2022.109161_b0565","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"7830","key":"10.1016\/j.intimp.2022.109161_b0570","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.intimp.2022.109161_b0575","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2013developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"Pt B","key":"10.1016\/j.intimp.2022.109161_b0580","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"N Biotechnol"},{"key":"10.1016\/j.intimp.2022.109161_b0585","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.701501","article-title":"SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants","volume":"12","author":"Mart\u00ednez-Flores","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00393-6","article-title":"Scientific rationale for developing potent RBD-based vaccines targeting COVID-19","volume":"6","author":"Kleanthous","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.intimp.2022.109161_b0595","doi-asserted-by":"crossref","unstructured":"F. Rahimi, A. Talebi Bezmin Abadi, Implications of the Emergence of a New Variant of SARS-CoV-2, VUI-202012\/01, Archives of medical research (2021).","DOI":"10.1016\/j.arcmed.2021.01.001"},{"key":"10.1016\/j.intimp.2022.109161_b0600","article-title":"Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review","volume":"173620","author":"Yarmohammadi","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109161_b0605","first-page":"332","article-title":"The mechanistic target of rapamycin (mTOR): novel considerations as an antiviral treatment","volume":"17","author":"Maiese","year":"2020","journal-title":"Curr. Neurovasc. Res."},{"key":"10.1016\/j.intimp.2022.109161_b0610","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2147\/NDT.S75717","article-title":"Activation of mTOR: a culprit of Alzheimer\u2019s disease?","volume":"11","author":"Cai","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.intimp.2022.109161_b0615","doi-asserted-by":"crossref","first-page":"100765","DOI":"10.1016\/j.genrep.2020.100765","article-title":"mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19","author":"Ramaiah","year":"2020","journal-title":"Gene Reports"},{"key":"10.1016\/j.intimp.2022.109161_b0620","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3389\/fphar.2020.00856","article-title":"An open question: is it rational to inhibit the mTor-dependent pathway as COVID-19 therapy?","volume":"11","author":"Terrazzano","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109161_b0625","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109161_b0630","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0635","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.109161_b0640","first-page":"1","article-title":"JAK\/STAT pathway inhibition may be a promising therapy for COVID-19-related hyperinflammation in hematologic patients","author":"Rojas","year":"2020","journal-title":"Acta Haematol."},{"key":"10.1016\/j.intimp.2022.109161_b0645","article-title":"Baricitinib plus Remdesivir for hospitalized adults with Covid-19","author":"Kalil","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109161_b0650","first-page":"152","article-title":"Convalescent plasma: new evidence for an old therapeutic tool?","volume":"14","author":"Marano","year":"2016","journal-title":"Blood transfusion = Trasfusione del sangue"},{"key":"10.1016\/j.intimp.2022.109161_b0655","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2015.12.003","article-title":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow","volume":"23","author":"Garraud","year":"2016","journal-title":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine"},{"key":"10.1016\/j.intimp.2022.109161_b0660","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109161_b0665","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1086\/519392","article-title":"West Nile virus neutralization by US plasma-derived immunoglobulin products","volume":"196","author":"Planitzer","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109161_b0670","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14712598.2020.1796963","article-title":"Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects","volume":"20","author":"Sharun","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2022.109161_b0675","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1213\/ane.0b013e3181930a6e","article-title":"Noninfectious serious hazards of transfusion","volume":"108","author":"Hendrickson","year":"2009","journal-title":"Anesth. Analg."},{"issue":"16","key":"10.1016\/j.intimp.2022.109161_b0680","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2022.109161_b0685","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e236","article-title":"The epidemiological and clinical characteristics of 81 children with COVID-19 in a pandemic hospital in Turkey: an observational cohort study","volume":"35","author":"Korkmaz","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.intimp.2022.109161_b0690","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.intimp.2022.109161_b0695","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2014mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.intimp.2022.109161_b0700","doi-asserted-by":"crossref","unstructured":"S. Wan, Q. Yi, S. Fan, J. Lv, X. Zhang, L. Guo, C. Lang, Q. Xiao, K. Xiao, Z. Yi, Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP), MedRxiv (2020).","DOI":"10.1101\/2020.02.10.20021832"},{"key":"10.1016\/j.intimp.2022.109161_b0705","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2022.109161_b0710","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2022.109161_b0715","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109161_b0720","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.intimp.2022.109161_b0725","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2022.109161_b0730","doi-asserted-by":"crossref","unstructured":"A. Gharbharan, C.C.E. Jordans, C. GeurtsvanKessel, J.G. den Hollander, F. Karim, F.P.N. Mollema, J.E. Stalenhoef, A. Dofferhoff, I. Ludwig, A. Koster, Convalescent Plasma for COVID-19. A randomized clinical trial, MEDRxiv (2020).","DOI":"10.1101\/2020.07.01.20139857"},{"key":"10.1016\/j.intimp.2022.109161_b0735","doi-asserted-by":"crossref","unstructured":"M.E. Balcells, L. Rojas, N. Le Corre, C. Mart\u00ednez-Valdebenito, M.E. Ceballos, M. Ferr\u00e9s, M. Chang, C. Vizcaya, S. Mondaca, \u00c1. Huete, Early anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial, medRxiv (2020).","DOI":"10.1101\/2020.09.17.20196212"},{"key":"10.1016\/j.intimp.2022.109161_b0740","article-title":"Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy","author":"Joyner","year":"2020","journal-title":"J. medRxiv"},{"key":"10.1016\/j.intimp.2022.109161_b0745","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults","volume":"384","author":"Libster","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109161_b0750","article-title":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study","volume":"59","author":"Abolghasemi","year":"2020","journal-title":"Transfusion Apheresis Sci.: Off. J. World Apheresis Assoc. : Off. J. Eur. Soc. Haemapheresis"},{"key":"10.1016\/j.intimp.2022.109161_b0755","first-page":"m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.intimp.2022.109161_b0760","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.ajpath.2020.05.014","article-title":"Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma","volume":"190","author":"Salazar","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.intimp.2022.109161_b0765","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109161_b0770","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jca.21806","article-title":"Convalescent plasma therapy in patients with COVID-19","volume":"35","author":"Yi\u011feno\u011flu","year":"2020","journal-title":"J. Clin. Apheresis"},{"key":"10.1016\/j.intimp.2022.109161_b0775","doi-asserted-by":"crossref","first-page":"102554","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: Possible mechanisms of action","author":"Rojas","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2022.109161_b0780","doi-asserted-by":"crossref","first-page":"100069","DOI":"10.1016\/j.jtauto.2020.100069","article-title":"Why will it never be known if convalescent plasma is effective for COVID-19","author":"Rojas","year":"2020","journal-title":"J. Transl. Autoimmunity"},{"key":"10.1016\/j.intimp.2022.109161_b0785","doi-asserted-by":"crossref","unstructured":"X. Zou, K. Chen, J. Zou, P. Han, J. Hao, Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, (2020).","DOI":"10.1007\/s11684-020-0754-0"},{"key":"10.1016\/j.intimp.2022.109161_b0790","doi-asserted-by":"crossref","unstructured":"Y.-r. Guo, Q.-d. Cao, Z.-s. Hong, Y.-y. Tan, S.-d. Chen, H.-j. Jin, K.-s. Tan, D.-y. Wang, Y. Yan, The origin , transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak \u2013 an update on the status, (2020) 1-10.","DOI":"10.1186\/s40779-020-00240-0"},{"key":"10.1016\/j.intimp.2022.109161_b0795","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.intimp.2022.109161_b0800","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109161_b0805","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.109161_b0810","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109161_b0815","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2022.109161_b0820","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.109161_b0825","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.109161_b0830","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/2159-8290.CD-20-0451","article-title":"TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?","volume":"10","author":"Stopsack","year":"2020","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.intimp.2022.109161_b0835","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.109161_b0840","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"ChemBioChem"},{"key":"10.1016\/j.intimp.2022.109161_b0845","first-page":"1","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2022.109161_b0850","doi-asserted-by":"crossref","first-page":"198021","DOI":"10.1016\/j.virusres.2020.198021","article-title":"On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2","volume":"285","author":"Giron","year":"2020","journal-title":"Virus Res"},{"key":"10.1016\/j.intimp.2022.109161_b0855","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?","volume":"134","author":"Batlle","year":"2020","journal-title":"Clin. Sci."},{"key":"10.1016\/j.intimp.2022.109161_b0860","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109161_b0865","doi-asserted-by":"crossref","first-page":"e13426","DOI":"10.15252\/emmm.202013426","article-title":"Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection","volume":"13","author":"Monteil","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"2020","key":"10.1016\/j.intimp.2022.109161_b0870","first-page":"1721","article-title":"CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 COVID-19","volume":"92","author":"Sun","year":"2019","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2022.109161_b0875","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2022.109161_b0880","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.mce.2009.12.022","article-title":"Androgen receptor and androgen-dependent gene expression in lung","volume":"317","author":"Mikkonen","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.intimp.2022.109161_b0885","article-title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are predominantly expressed in a transient secretory cell type in subsegmental bronchial branches","author":"Lukassen","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.intimp.2022.109161_b0890","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle","year":"2020","journal-title":"Life Sci. Alliance"},{"issue":"3","key":"10.1016\/j.intimp.2022.109161_b0895","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jmii.2020.02.012","article-title":"Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths","volume":"53","author":"Lai","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"15","key":"10.1016\/j.intimp.2022.109161_b0900","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109161_b0905","doi-asserted-by":"crossref","first-page":"104859","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2022.109161_b0910","unstructured":"J. Uttamani, G. Fernandes, S. Pandey, V. Surabathula, D. Bhat, (2020)."},{"issue":"7","key":"10.1016\/j.intimp.2022.109161_b0915","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/jac\/dkaa114","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","volume":"75","author":"Zhou","year":"2020","journal-title":"J. Antimicrobial Chemother."},{"key":"10.1016\/j.intimp.2022.109161_b0920","doi-asserted-by":"crossref","first-page":"m1844","DOI":"10.1136\/bmj.m1844","article-title":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","volume":"369","author":"Mahevas","year":"2020","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.intimp.2022.109161_b0925","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.msec.2013.04.021","article-title":"Bactericidal property and biocompatibility of gentamicin-loaded mesoporous carbonated hydroxyapatite microspheres","volume":"33","author":"Guo","year":"2013","journal-title":"Mater. Sci. Eng., C"},{"key":"10.1016\/j.intimp.2022.109161_b0930","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejim.2020.08.019","article-title":"Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study","volume":"82","author":"Covid","year":"2020","journal-title":"Eur. J. Int. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0935","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"21","key":"10.1016\/j.intimp.2022.109161_b0940","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"I.I. Coalition Covid-19 Brazil, Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109161_b0945","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N Engl. J. Med."},{"issue":"25","key":"10.1016\/j.intimp.2022.109161_b0950","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.109161_b0955","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"f.t.C.-Team, Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Network Open"},{"issue":"26","key":"10.1016\/j.intimp.2022.109161_b0960","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016239","article-title":"Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: a meta-analysis","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b0965","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13054-020-02964-w","article-title":"Adjuvant corticosteroid therapy for critically ill patients with COVID-19","volume":"24","author":"Lu","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.intimp.2022.109161_b0970","first-page":"ciaa351","article-title":"Factors associated with prolonged viral RNA shedding in patients with COVID-19 [published online ahead of print, 2020 Apr 9]","author":"Xu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109161_b0975","article-title":"Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report","author":"Group","year":"2020","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109161_b0980","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/CM9.0000000000000819","article-title":"Diagnosis and treatment Protocol for novel coronavirus pneumonia (trial version 7)","volume":"133","author":"Commission","year":"2020","journal-title":"Chinese Med. J."},{"key":"10.1016\/j.intimp.2022.109161_b0985","unstructured":"W.D.-G.s.o.r.a.t.m.b.o.C.-. June, https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-re, m.-a.-t.-m.-b.-o.-c.-.-.-j.-A.J. 2020)."},{"issue":"5","key":"10.1016\/j.intimp.2022.109161_b0990","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost"},{"key":"10.1016\/j.intimp.2022.109161_b0995","doi-asserted-by":"crossref","first-page":"100562","DOI":"10.1016\/j.eclinm.2020.100562","article-title":"Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study","volume":"27","author":"Albani","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.intimp.2022.109161_b1000","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1017\/S0950268820000254","article-title":"SARS to novel coronavirus - old lessons and new lessons","volume":"148","author":"McCloskey","year":"2020","journal-title":"Epidemiol. Infect."},{"issue":"2","key":"10.1016\/j.intimp.2022.109161_b1005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11239-020-02162-z","article-title":"The association between treatment with heparin and survival in patients with Covid-19","volume":"50","author":"Ayerbe","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.intimp.2022.109161_b1010","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.569567","article-title":"Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study","volume":"7","author":"Russo","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2022.109161_b1015","doi-asserted-by":"crossref","first-page":"101647","DOI":"10.1016\/j.tmaid.2020.101647","article-title":"Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence","volume":"35","author":"Cao","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109161_b1020","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.2147\/DDDT.S261154","article-title":"A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19","volume":"14","author":"Hashemian","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"21","key":"10.1016\/j.intimp.2022.109161_b1025","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17218155","article-title":"COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies","volume":"17","author":"Rauf","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"3","key":"10.1016\/j.intimp.2022.109161_b1030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2022.109161_b1035","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","author":"Holshue","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.intimp.2022.109161_b1040","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate Use of Remdesivir for Patients with Severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109161_b1045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/biologics1020016","article-title":"Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far","volume":"1","author":"Hossain","year":"2021","journal-title":"Biologics"},{"issue":"10236","key":"10.1016\/j.intimp.2022.109161_b1050","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.intimp.2022.109161_b1055","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.intimp.2022.109161_b1060","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.intimp.2022.109161_b1065","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 - Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109161_b1070","doi-asserted-by":"crossref","unstructured":"R. Perveen, M. Nasir, M. Murshed, R. Naznin, S. Ahmad, Remdesivir and Favipiravir Changes Hepato-Renal Profile in COVID-19 Patients: A Cross Sectional Observation in Bangladesh, (2021).","DOI":"10.18535\/ijmsci\/v8i01.03"},{"key":"10.1016\/j.intimp.2022.109161_b1075","article-title":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","volume":"369","author":"Mah\u00e9vas","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2022.109161_b1080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejim.2020.08.019","article-title":"Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study","volume":"82","author":"Di Castelnuovo","year":"2020","journal-title":"Eur. J. Int. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b1085","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"21","key":"10.1016\/j.intimp.2022.109161_b1090","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109161_b1095","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.intimp.2022.109161_b1100","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.109161_b1105","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.intimp.2022.109161_b1110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-02964-w","article-title":"Adjuvant corticosteroid therapy for critically ill patients with COVID-19","volume":"24","author":"Lu","year":"2020","journal-title":"Crit. Care"},{"issue":"8","key":"10.1016\/j.intimp.2022.109161_b1115","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109161_b1120","doi-asserted-by":"crossref","first-page":"569567","DOI":"10.3389\/fmed.2020.569567","article-title":"Thromboprofilaxys with fondaparinux vs. enoxaparin in hospitalized COVID-19 patients: a multicenter Italian observational study","volume":"7","author":"Russo","year":"2020","journal-title":"Front. Med."},{"issue":"24","key":"10.1016\/j.intimp.2022.109161_b1125","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10236","key":"10.1016\/j.intimp.2022.109161_b1130","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"The lancet"},{"issue":"19","key":"10.1016\/j.intimp.2022.109161_b1135","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:41:44Z","timestamp":1761586904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922006452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":227,"alternative-id":["S1567576922006452"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109161","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109161"}}